Skip to main content

Table 2 Annual prevalence (2003–2008) of pharmacologically treated ADHD (methylphenidate, dexamfetamine and atomoxetine) by age category and gender

From: The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care

Age Category

Year

2003

2004

2005

2006

2007

2008

Total Prevalence*1000 (Males and Females ≥ 6 years)

0.709

0.862

1.014

1.203

1.365

1.403

95% Cl (lb)*1000

0.676

0.825

0.975

1.161

1.320

1.358

95% Cl (ub)*1000

0.743

0.899

1.054

1.246

1.411

1.449

6-12 years

Female Prevalence*1000

1.339

1.642

2.042

2.310

2.775

2.769

95% Cl (lb)*1000

1.131

1.411

1.784

2.034

2.470

2.464

95% Cl (ub)*1000

1.574

1.900

2.327

2.613

3.108

3.101

Male Prevalence*1000

8.147

9.758

11.133

13.224

15.432

15.321

95% Cl (lb)*1000

7.634

9.195

10.532

12.566

14.716

14.607

95% Cl (ub)*1000

8.685

10.346

11.759

13.907

16.174

16.061

Total Prevalence*1000

4.825

5.795

6.688

7.886

9.241

9.181

95% Cl (lb)*1000

4.543

5.485

6.355

7.522

8.844

8.786

95% Cl (ub)*1000

5.121

6.119

7.034

8.262

9.651

9.590

13-17 years

Female Prevalence*1000

0.635

0.947

1.106

1.446

1.767

2.002

95% Cl (lb)*1000

0.465

0.742

0.890

1.201

1.497

1.714

95% Cl (ub)*1000

0.847

1.191

1.360

1.727

2.071

2.325

Male Prevalence*1000

6.250

7.535

9.104

11.027

11.752

12.569

95% Cl (lb)*1000

5.719

6.963

8.485

10.350

11.054

11.845

95% Cl (ub)*1000

6.818

8.141

9.757

11.737

12.483

13.325

Total Prevalence*1000

3.608

4.404

5.265

6.378

6.865

7.396

95% Cl (lb)*1000

3.314

4.087

4.925

6.008

6.484

6.999

95% Cl (ub)*1000

3.921

4.739

5.622

6.765

7.264

7.810

18-24 years

Female Prevalence*1000

0.118

0.116

0.112

0.244

0.337

0.335

95% Cl (lb)*1000

0.059

0.058

0.056

0.158

0.236

0.237

95% Cl (ub)*1000

0.211

0.207

0.200

0.361

0.466

0.460

Male Prevalence*1000

0.396

0.521

0.845

0.943

1.385

1.876

95% Cl (lb)*1000

0.283

0.391

0.679

0.770

1.178

1.637

95% Cl (ub)*1000

0.540

0.680

1.038

1.142

1.619

2.140

Total Prevalence*1000

0.263

0.327

0.493

0.607

0.878

1.122

95% Cl (lb)*1000

0.196

0.253

0.402

0.507

0.759

0.989

95% Cl (ub)*1000

0.346

0.417

0.599

0.721

1.010

1.267

25-45 years

Female Prevalence*1000

0.008

0.026

0.028

0.040

0.045

0.052

95% Cl (lb)*1000

0.002

0.012

0.014

0.023

0.027

0.032

95% Cl (ub)*1000

0.023

0.047

0.050

0.065

0.071

0.079

Male Prevalence*1000

0.025

0.038

0.052

0.074

0.095

0.105

95% Cl (lb)*1000

0.012

0.021

0.032

0.050

0.068

0.076

95% Cl (ub)*1000

0.046

0.062

0.079

0.105

0.130

0.141

Total Prevalence*1000

0.017

0.032

0.040

0.057

0.070

0.079

95% Cl (lb)*1000

0.009

0.021

0.027

0.042

0.053

0.061

95% Cl (ub)*1000

0.028

0.047

0.056

0.076

0.091

0.100

>45 years

Female Prevalence*1000

0.007

0.011

0.007

0.010

0.010

0.011

95% Cl (lb)*1000

0.002

0.004

0.002

0.004

0.004

0.005

95% Cl (ub)*1000

0.018

0.023

0.018

0.022

0.022

0.024

Male Prevalence*1000

0.008

0.008

0.015

0.015

0.020

0.027

95% Cl (lb)*1000

0.002

0.002

0.007

0.006

0.010

0.015

95% Cl (ub)*1000

0.020

0.020

0.030

0.029

0.036

0.044

Total Prevalence*1000

0.008

0.009

0.011

0.012

0.015

0.019

95% Cl (lb)*1000

0.003

0.004

0.006

0.007

0.009

0.012

95% Cl (ub)*1000

0.015

0.017

0.019

0.021

0.024

0.028

  1. CI (Confidence Interval), lb (lower boundary) and ub (upper boundary).